Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty seven patients were enrolled in various clinical trials of ibrutinib with/without rituximab at our center. Thirty three (26%) patients have discontinued ibrutinib to date. The majority of those patients had high risk features; 94% unmutated IGHV, 58% with del(17p) by FISH, and 54% with a complex karyotype. Causes of discontinuation were disease transformation (7), progressive CLL (7), stem cell transplantation (3), adverse events (11), serious adverse events/deaths (3) and 2 had miscellaneous reasons. Twenty five patients (76%) died after discontinuing ibrutinib; the median overall survival was 3.1 months after discontinuation. Most relapsed refractory patients with CLL who discontinued ibrutinib early were difficult to treat and had poor outcomes.
Introduction: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B cell receptor (BCR) signaling pathway 1 and is a novel therapeutic target in CLL. or in combination with rituximab has demonstrated favorable results in patients with relapsed CLL and high risk disease [e.g. del(17p)].
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In a phase 3 trial 6 , patients with RR-CLL were randomized between treatment with ibrutinib 420 mg orally daily (n=195) or ofatumumab monotherapy (n=196). As per the investigator's assessment the ORR (CR + PR + PR with lymphocytosis) was 85% in the ibrutinib arm vs 24% in the ofatumumab arm. Ibrutinib was well tolerated. The most common adverse effects were diarrhea, fatigue, pyrexia, nausea, anemia and neutropenia seen in >20% patients. Grade 3-4 hematological toxicity was comparable in the ibrutinib arm vs the ofatumumab arm -neutropenia (16% vs 14%), anemia (5% vs 8%) and thrombocytopenia (6% vs 4%).
Bleeding such as petechiae or ecchymosis was more frequent in patients treated with ibrutinib 44% vs 12% in those treated with ofatumumab, however major bleeding requiring red blood cell transfusion or hospitalization was 1% vs 2% with ibrutinib vs ofatumumab respectively. Grade 3 non-hematological adverse effects were diarrhea and atrial fibrillation (4% and 3% in the ibrutinib arm). Of note, atrial fibrillation (any grade) occurred in 5% vs 1% of patients treated with ibrutinib vs ofatumumab. Fourteen percent (n=28) of patients discontinued therapy after a median follow up of 9.5 months. The most common causes of discontinuation of ibrutinib were disease progression, adverse events, deaths, patient decision and stem cell transplant (SCT). Ibrutinib improved response rates, PFS and the overall survival compared to ofatumumab in patients with RR-CLL.
In a phase 2 trial 3,4 of 85 (117 in 2013 update) patients with RR-CLL treated with single agent ibrutinib, 36%
(n=31) of patients discontinued therapy after a median follow up of 21 months. The most common causes of discontinuation of ibrutinib were disease progression, adverse events, patient decision and stem cell transplant For personal use only. on October 4, 2017. by guest www.bloodjournal.org From patients died and 8 are alive. Six were on study deaths (Table-3 ). Of note, the rates of unmutated IGHV, 17p deletion and complex karyotype for the 94 patients who did not discontinue ibrutinib therapy were 74%, 25% and 46% respectively. The rate of 17p deletion and unmutated IGHV were significantly higher in patients who discontinued ibrutinib therapy (P=0.0005 and 0.02 respectively).
Seven patients transformed to an aggressive lymphoma; 6 had diffuse large B cell lymphoma (Richter's transformation) and one patient had a histiocytic sarcoma discovered only at autopsy. The cause of death in the patient with histiocytic sarcoma transformation was multiorgan dysfunction secondary to histiocytic sarcoma transformation. Four (58%) patients transformed within the first 12 months of starting ibrutinib. Among these seven patients 6 (86%) have died; one patient died on study (transformation found at autopsy). One patient with Richter's transformation is alive and being treated with a small molecule in a clinical trial. Among the six patients who died, 2 died within a month due to sepsis and disease progression without further therapy. Three died within 3 months after treatment with intensive chemoimmunotherapy (n=2) or an investigational agent (n=1). One patient failed chemoimmunotherapy and died in hospice after 15 months.
Seven patients progressed without transformation. Four patients are alive and 3 patients died. Among the three patients who died, 2 had pneumonia and progressive disease and 1 patient failed to respond to further therapy.
Four patients are alive -two are receiving investigational agents, one responded to ofatumumab and one patient is not receiving therapy.
Three patients responding to ibrutinib proceeded to SCT; two patient have died and another is alive and in remission. Two patients died due to complications of SCT and severe graft versus host disease (GVHD).
Fourteen patients came off therapy due to adverse events (n=11) or death (n=3). Adverse events included extensive aspergillosis, diarrhea and subdural hematoma, recurrent ear bleeding, recurrent oral ulcers, subdural hematoma and atrial fibrillation, pseudomonas sepsis, extensive fungal pneumonia, diarrhea and pneumonia, recurrent infections, gastrointestinal bleeding, colitis (summarized in table-3).
Two patients discontinued ibrutinib due to other reasons including therapy related myelodysplasia (prior therapy with fludarabine and bendamustine) and financial issues. 6-20 months) . In addition to the patient dying of transformation to histiocytic sarcoma there were 5 other deaths on study. Two patients died suddenly at home (cause of death is unknown in the two) and one patient committed suicide due to depression. Two patients developed severe infections.
We assessed whether there was any difference in the causes of discontinuation between patients enrolled on studies with rituximab (n=15) vs without (n=18). Of 15 patients treated with rituximab and ibrutinib two patients discontinued due to transformation, 4 due to disease progression, 2 due to SCT and 7 secondary to adverse events (including one due to suicide). There does not appear to be any significant difference in reasons for discontinuation between patients enrolled on studies with rituximab vs without.
Of the 33 patients in this analysis, only 3 patients were previously untreated and they discontinued ibrutinib secondary to Richter's transformation, suicide and recurrent ear bleeding. Figure-1 shows the survival of patients after discontinuing ibrutinib. The median survival for all the patients was 3.1 months and did not differ significantly between transformed and untransformed (those who progressed and those who discontinued due to other reasons) patients with CLL. We also compared the post ibrutinib survival of patients who transformed with those patients who progressed with CLL (Figure-2) . Median survival in patients who progressed (untransformed) was not reached vs 2.6 months in those who transformed. There was no significant difference in survival (p=0.44).
Discussion: Our data suggests that survival of most previously treated patients who discontinued ibrutinib 'early' is poor and few salvage treatment options are available for these patients. The median duration of ibrutinib therapy before discontinuation in our study population was 13 months. In the most recent follow up of the phase 2 study of ibrutinib, the median PFS was not reached at 30 months. In our analysis, all but 3 patients relapsed before the median of 30 months and therefore are considered as "early" progressors, partly accounting for such poor outcomes. 8 Another possible reason for poor salvagibility of these patients after discontinuing ibrutinib could be due to higher proportion of these patients having del(17p) (58% vs 25%) and unmutated 
